Tracking mosquito-borne and other emerging virus infections in Fiji

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a longitudinal household cohort in Fiji's Central Division that enrolls residents aged 6 years and older and follows them over time to measure exposure to arboviruses (like dengue, Zika, chikungunya) and respiratory viruses (including influenza and SARS-CoV-2). Participants provide health questionnaires and biological samples at set visits so researchers can measure antibodies and detect infections. The work is coordinated locally by Fiji National University with laboratory and analytic collaboration from regional and international partners. Results will map seroprevalence, changes in immunity, and patterns of virus circulation across seasons and years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals aged 6 years and older who reside in the Central Division of Fiji
* Have lived in the selected household for at least six months at the time of enrollment

Exclusion Criteria:

* Pregnant women;
* Women in labor, or breastfeeding mothers;
* Individuals deprived of liberty by judicial or administrative decision;
* Individuals under psychiatric care or admitted to a health or social care facility for purposes other than participation in the study;
* Adults under legal protection or unable to provide informed consent;
* Homeless individuals;
* Individuals with severe disabilities preventing mobility;
* Individuals unable to understand or complete the study questionnaire

Where it's running

• Fiji National University
  Suva, Central, Fiji Recruiting

Study contacts

• Principal investigator: Donald Wilson, MBBS, PhD-Epidemiology — Fiji National University
• Study coordinator: Isireli Koroituku, Masters Infectious Diseases
• Email: isireli.koroituku@fnu.ac.fj
• Phone: +679 9090729

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Passive RSV antibody to protect Aboriginal and Torres Strait Islander infants

  This trial tests whether giving a single shot of the RSV antibody nirsevimab to Aboriginal and Torres Strait Islander infants around 6 months old can reduce RSV infections in the first year of life.

  Recruiting Phase 4 Menzies School of Health Research · Darwin, Northern Territory · NCT07578298

• Characterizing T-cell responses to arbovirus infections using ELISpot tests

  This project will test whether ELISpot blood assays can detect T-cell immune responses in adults with suspected arbovirus infections.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07291206

• Preparedness through community respiratory virus testing and engagement

  This program will offer community members regular testing for respiratory viruses like COVID-19, flu, and RSV and invite some people to join longer-term monitoring and household transmission follow-up.

  Recruiting at 2 sites University of California, San Diego · La Jolla, California and 1 other locations · NCT07147517

• How viral infections affect people with chronic lung disease

  This study will test if respiratory viruses trigger flare-ups and change immune responses in adults with COPD or bronchiectasis.

  Recruiting Imperial College London · London · NCT06625944

• Deuremidevir hydrobromide treatment for RSV in infants and young children

  This trial tests whether deuremidevir hydrobromide, given by weight three times daily for five days, helps infants and young children (1–36 months) with confirmed RSV recover faster or have milder symptoms than a placebo.

  Recruiting at 2 sites Phase 3 Simcere Pharmaceutical Co., Ltd · Xiamen, Fujian and 3 other locations · NCT07402512

• RSV strains and illness burden in Vietnamese adults aged 60 and older

  This project will test how common RSV is and which strains and severity patterns occur in people aged 60+ who are hospitalized with acute respiratory illness or worsening heart/lung disease.

  Recruiting Tam Anh Research Institute · Ho Chi Minh City, Southern Vietnam · NCT07239583

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.